All In Biotech

Drug Trial Radar · NCT01822028

Two Period / Two Treatment Cross-over to Assess the Effect of Florastor® on Gastrointestinal Tolerability, Safety, and PK in Healthy Subjects Receiving Zavesca®

A Single-center, Double-blind, Randomized, Placebo-controlled, Two Period / Two Treatment Cross-over Study to Assess the Effect of Florastor® (Saccharomyces Boulardii Lyo) on Gastrointestinal Tolerability, Safety, and Pharmacokinetics of Zavesca® (Miglustat) in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Mar 10, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Mar 2013

Primary completion

Jun 2013

Study completion Aug 2013

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Apr 2, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Cross-over, tolerability study with healthy subjects taking Zavesca in combination with Florastor. Forty-two subjects will be randomized to one of two treatment sequences of Zavesca with Florastor and Zavesca with Placebo of Florastor. Gastrointestinal tolerability and PK endpoints, demographic, laboratory and safety testing, and AEs and SAEs will be collected throughout the seventy-four day study.

Conditions

  • Diarrhea

Interventions

  • Treatment ADrug

    Florastor® placebo. Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).

  • Treatment BDrug

    Florastor® capsules dosed at 1000 mg daily (two 250 mg capsules two times per day). Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. GASTROINTESTINAL TOLERABILITY ENDPOINTSTime frame: baseline to end of study (day 74)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • BioPharma Services Inc.

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.